세계의 지혈제 및 조직 실링제 시장 : 제품별, 재료별, 용도별, 최종사용자별, 지역별 예측(-2032년)

Global Hemostasis and Tissue Sealing Agents Market Research Report Information by Product (Topical Hemostat, Adhesive & Tissue Sealant), By Material (Chitosan-based Products, Mineral based Products), By Application (Trauma, General Surgery, Minimally Invasive Surgery, Gynecology Others), By End-User (Hospitals, Ambulatory Surgical Centers, Research Institutes), and Region (North America, Europe, Asia-Pacific, and Rest of the World) Forecast till 2032

Market Overview

In 2023, the market for hemostasis and tissue sealing agents was estimated to be worth USD 8.39 billion. The Hemostasis and Tissue Sealing Agents Market is expected to increase from USD 9.02 billion in 2024 to USD 18.19 billion by 2032, with a compound annual growth rate (CAGR) of 8.04% over the forecast period (2024-2032). Rising rates of traffic accidents and chronic blood problems, a global demand for minimally invasive procedures, and an aging population are driving market expansion.

The increasing prevalence of chronic blood diseases is another element driving market growth. Individuals with certain blood disorders, such as hemophilia or von Willebrand disease, are more likely to bleed because their clotting factors are compromised. Hemostasis drugs, which enhance blood clotting and limit bleeding, may be required in surgical procedures or medicinal interventions for people with these conditions. For example, the International Society on Thrombosis and Hemostasis' 2022 update estimates that approximately 10 million cases of venous thromboembolism occur globally each year. According to the same source, 544,000 persons in Europe die each year from Deep Vein Thrombosis (DVT).

Market Segment insights

Hemostasis and Tissue Sealing Agents Product-based market segmentation includes Topical Hemostat and adhesive & tissue sealant.

The market is segmented by material, which comprises chitosan-based products and mineral-based products.

The market is segmented by end user, which includes hospitals, ambulatory surgical centers, and research institutes.

Regional insights

The study divides the market into four regions: North America, Europe, Asia-Pacific, and the rest of the world. The North American Hemostasis and Tissue Sealing Agents market had the biggest market share in 2023. Because of the aging population, the rising prevalence of chronic diseases, and the ongoing advancement of medical technology. With a focus on improving patient outcomes and lowering postoperative complications, the market has evolved into a hub for research and development, resulting in the introduction of novel treatments with superior efficacy.

The European Hemostasis and Tissue Sealing Agents market is estimated to account for the second-largest market share due to favorable health policies and a tendency toward combining Hemostasis and Tissue Sealing Agents, including counseling. Furthermore, the German Hemostasis and Tissue Sealing Agents market was found to have the greatest market share, while the French Hemostasis and Tissue Sealing Agents market is predicted to be the fastest-growing market in the European area.

The Asia-Pacific Hemostasis and Tissue Sealing Agents market is estimated to develop at the quickest rate between 2024 and 2032. This is the result of rapid economic expansion, a growing middle class, and greater urbanization. The region's growing population fuels demand for healthcare, technology, and consumer products. Robust investments in infrastructure, education, and technology drive industrial development and innovation.

The Middle East, Africa, and Latin America are all part of the Rest of the World. The primary drivers driving the rise of Hemostasis and Tissue Sealing Agents in the Middle East and Africa. MEA region has experienced. Increased healthcare spending and infrastructure expansion are boosting demand for innovative medical equipment.

Key Market Players

Johnson & Johnson (US), B Braun Medical Inc (Germany), Teleflex Incorporated (US), Medtronic (Ireland), Baxter (US), Medtrade Products Limited (UK), Axio Biosolutions Pvt Ltd (India), MIL Laboratories Pvt. Ltd (India), Becton, Dickinson, and Company (US), and Pfizer Inc (US) are the market's leading players.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 Data Mining Process
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 Secondary Research data flow:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 Primary Research Data Flow:
  • 3.5.2 Primary Research: Number of Interviews conducted
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 Revenue Analysis Approach
• 3.7 DATA FORECASTING
  • 3.7.1 Data forecasting Technique
• 3.8 DATA MODELLING
  • 3.8.1 Microeconomic Factor Analysis:
  • 3.8.2 Data Modelling:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.1 DRIVERS
  • 4.1.1 Growing Incidences Of Road Accidents And Chronic Blood Disorders
  • 4.1.2 Growing Preference Of Minimally Invasive Procedures
• 4.2 RESTRAINTS
  • 4.2.1 High Costs and Stringent Regulatory Requirements
• 4.3 OPPORTUNITY
  • 4.3.1 Growing Incidences Of Road Accidents And Growing Geriatric Population

5 MARKET FACTOR ANALYSIS

• 5.1 VALUE CHAIN ANALYSIS
  • 5.1.1 Research & Development
  • 5.1.2 Manufacturing
  • 5.1.3 Distribution
  • 5.1.4 Marketing & Sales
  • 5.1.5 Post-Sales Monitoring
• 5.2 PORTER'S FIVE FORCES MODEL
  • 5.2.1 bargaining power of buyers
  • 5.2.2 Bargaining Power of Suppliers
  • 5.2.3 Threat of New Entrants
  • 5.2.4 THREAT OF SUBSTITUTES
  • 5.2.5 Intensity of Rivalry
• 5.3 IMPACT OF COVID-19
• 5.4 HEMOSTASIS AND TISSUE SEALING AGENTS FOR MILITARY PURPOSE

6 GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET, BY PRODUCT

• 6.1 OVERVIEW
• 6.2 TOPICAL HEMOSTAT
  • 6.2.1 Active
  • 6.2.2 Mechanical
  • 6.2.3 Flowable
• 6.3 ADHESIVE & TISSUE SEALANT
  • 6.3.1 Synthetic Tissue Sealant
  • 6.3.2 Natural Tissue Sealant
  • 6.3.3 Adhesion Barrier Products

7 GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET, BY MATERIAL

• 7.1 OVERVIEW
• 7.2 CHITOSAN-BASED PRODUCTS
• 7.3 MINERAL BASED PRODUCTS

8 GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET, BY APPLICATION

• 8.1 OVERVIEW
• 8.2 TRAUMA
  • 8.2.1 Burns
  • 8.2.2 Accidents
    • 8.2.2.1 Major Accidents
    • 8.2.2.2 Minor Accidents
  • 8.2.3 Others
• 8.3 GENERAL SURGERY
• 8.4 MINIMALLY INVASIVE SURGERY
• 8.5 GYNAECOLOGY
• 8.6 OTHERS

9 GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET, BY END USER

• 9.1 OVERVIEW
• 9.2 HOSPITALS
  • 9.2.1 Public
  • 9.2.2 Private
  • 9.2.3 Military
• 9.3 AMBULATORY SURGICAL CENTERS
  • 9.3.1 Independent Ambulatory Surgical Centers
  • 9.3.2 Military Ambulatory Surgical Centers
• 9.4 RESEARCH INSTITUTES

10 GLOBAL HEMOSTASIS AND TISSUE SEALING AGENTS MARKET, BY REGION

• 10.1 OVERVIEW
• 10.2 NORTH AMERICA
  • 10.2.1 US
  • 10.2.2 CANADA
• 10.3 EUROPE
  • 10.3.1 Germany
  • 10.3.2 France
  • 10.3.3 UK
  • 10.3.4 Italy
  • 10.3.5 spain
  • 10.3.6 Rest of Europe
• 10.4 ASIA-PACIFIC
  • 10.4.1 China
  • 10.4.2 India
  • 10.4.3 Japan
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia-Pacific
• 10.5 REST OF THE WORLD
  • 10.5.1 Middle East & Africa
  • 10.5.2 South America

11 COMPETITIVE LANDSCAPE

• 11.1 INTRODUCTION
• 11.2 MARKET SHARE ANALYSIS,
• 11.3 COMPETITOR DASHBOARD
• 11.4 PUBLIC PLAYERS STOCK SUMMARY
• 11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
• 11.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 11.6.1 product launch / Product approval
  • 11.6.2 Acquisition

12 COMPANY PROFILES

• 12.1 JOHNSON & JOHNSON SERVICES, INC
  • 12.1.1 COMPANY OVERVIEW
  • 12.1.2 FINANCIAL OVERVIEW
  • 12.1.3 productS OFFERED
  • 12.1.4 KEY DEVELOPMENTS
  • 12.1.5 SWOT ANALYSIS
  • 12.1.6 KEY STRATEGIES
• 12.2 B. BRAUN SE
  • 12.2.1 COMPANY OVERVIEW
  • 12.2.2 FINANCIAL OVERVIEW
  • 12.2.3 products OFFERED
  • 12.2.4 KEY DEVELOPMENTS
  • 12.2.5 KEY STRATEGIES
• 12.3 MIL LABORATORIES PVT. LTD
  • 12.3.1 COMPANY OVERVIEW
  • 12.3.2 FINANCIAL OVERVIEW
  • 12.3.3 productS OFFERED
  • 12.3.4 KEY DEVELOPMENTS
  • 12.3.5 KEY STRATEGIES
• 12.4 BECTON, DICKINSON, AND COMPANY
  • 12.4.1 COMPANY OVERVIEW
  • 12.4.2 FINANCIAL OVERVIEW
  • 12.4.3 PRODUCTS OFFERED
  • 12.4.4 KEY DEVELOPMENTS
  • 12.4.5 KEY STRATEGIES
• 12.5 PFIZER INC.
  • 12.5.1 COMPANY OVERVIEW
  • 12.5.2 FINANCIAL OVERVIEW
  • 12.5.3 PRODUCTS OFFERED
  • 12.5.4 KEY DEVELOPMENTS
  • 12.5.5 SWOT ANALYSIS
  • 12.5.6 KEY STRATEGIES
• 12.6 TELEFLEX INCORPORATED
  • 12.6.1 COMPANY OVERVIEW
  • 12.6.2 FINANCIAL OVERVIEW
  • 12.6.3 PRODUCTS OFFERED
  • 12.6.4 KEY DEVELOPMENTS
  • 12.6.5 TELEFLEX INCORPORATED: kEY DEVELOPMENTS
  • 12.6.6 KEY STRATEGIES
• 12.7 MEDTRONIC
  • 12.7.1 COMPANY OVERVIEW
  • 12.7.2 FINANCIAL OVERVIEW
  • 12.7.3 PRODUCTS OFFERED
  • 12.7.4 KEY DEVELOPMENTS
  • 12.7.5 SWOT ANALYSIS
  • 12.7.6 KEY STRATEGIES
• 12.8 BAXTER
  • 12.8.1 COMPANY OVERVIEW
  • 12.8.2 FINANCIAL OVERVIEW
  • 12.8.3 PRODUCTS OFFERED
  • 12.8.4 KEY DEVELOPMENTS
  • 12.8.5 SWOT ANALYSIS
  • 12.8.6 KEY STRATEGIES
• 12.9 MEDTRADE PRODUCTS LIMITED
  • 12.9.1 COMPANY OVERVIEW
  • 12.9.2 FINANCIAL OVERVIEW
  • 12.9.3 PRODUCTS OFFERED
  • 12.9.4 KEY DEVELOPMENTS
  • 12.9.5 SWOT ANALYSIS
  • 12.9.6 KEY STRATEGIES
• 12.10 AXIO BIOSOLUTIONS PVT LTD
  • 12.10.1 COMPANY OVERVIEW
  • 12.10.2 FINANCIAL OVERVIEW
  • 12.10.3 PRODUCTS OFFERED
  • 12.10.4 KEY DEVELOPMENTS
  • 12.10.5 KEY STRATEGIES

13 DATA CITATIONS